Highlights
2024
Launch and sales start of Cellevat3d™ carriers in bioprocess applications.
2023
Closing of investment round of 39 MSEK for Cellevate scale-up and commercialization of Cellevat3d™ nanotechnology in upstream bioprocessing: organization, QMS, ISO 9001, production, development, IP, sales and marketing.
2022
New strategy: Cellevat3d™ nanofiber-based upstream bioprocessing solutions.
New CEO, Management Team and Scientific Advisory Board.
2 x patents filed for production methods of micro- and macrocarriers.
2.48 MEUR EIC Accelerator grant and 3 MEUR equity investment for commercialization of Cellevat3d™ carriers.
2017
First Cellevat3d™ nanotechnology-based products are customized and sold as R&D Customized Solutions for cell co-culture research applications in neurology, immunology and cancer.
2014
Cellevate is founded as a spinout from NanoLund and Prof. Lars Montelius group.
